MDxHealth SA (NASDAQ:MDXH) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of MDxHealth SA (NASDAQ:MDXH) have been given an average rating of “Moderate Buy” by the five brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.75.

MDXH has been the topic of a number of recent analyst reports. BTIG Research reaffirmed a “buy” rating and set a $7.00 target price on shares of MDxHealth in a research report on Tuesday, December 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Kennedy Capital Management LLC purchased a new stake in shares of MDxHealth in the 3rd quarter valued at approximately $1,826,000. FreeGulliver LLC grew its position in MDxHealth by 25.7% during the 4th quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock worth $1,135,000 after purchasing an additional 65,000 shares in the last quarter. Mink Brook Asset Management LLC grew its position in MDxHealth by 64.9% during the 4th quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock worth $940,000 after purchasing an additional 103,686 shares in the last quarter. Renaissance Technologies LLC raised its stake in MDxHealth by 23.3% during the 4th quarter. Renaissance Technologies LLC now owns 250,100 shares of the company’s stock valued at $893,000 after purchasing an additional 47,300 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of MDxHealth by 96.0% in the fourth quarter. Russell Investments Group Ltd. now owns 194,097 shares of the company’s stock valued at $693,000 after purchasing an additional 95,054 shares in the last quarter.

MDxHealth Stock Performance

MDxHealth stock opened at $3.36 on Wednesday. The firm has a market cap of $166.32 million, a price-to-earnings ratio of -5.01 and a beta of 1.61. MDxHealth has a 1 year low of $1.36 and a 1 year high of $5.33. The firm’s 50 day moving average price is $3.52 and its two-hundred day moving average price is $3.78.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Thursday, February 26th. The company reported $999.00 EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $999.13. The company had revenue of $29.55 million during the quarter, compared to the consensus estimate of $26.05 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%. As a group, equities analysts predict that MDxHealth will post -1.15 EPS for the current fiscal year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.